Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the potential to overcome treatment resistance to…

Continue Reading

News Source: medicalxpress.com